All In Biotech

Drug Trial Radar · NCT04368806

A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis

A 48-Weeks, Phase 2b/3a, Double-Blind, Randomized, Placebo Controlled, Multi-center, Superiority Study to Evaluate the Efficacy and Safety of JointStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells in Patients Diagnosed as Knee Osteoarthritis

Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 173 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

173

Actual

Start

May 26, 2021

Primary completion

Aug 6, 2027

Study completion Aug 7, 2027

Sponsor

Lead sponsor
Nature Cell Co. Ltd.Industry
Sponsor type
Industry
First posted
Apr 30, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a double-blind, randomized, placebo controlled, multi-center, superiority study to evaluate the efficacy and safety of JointStem, autologous adipose tissue derived mesenchymal stem cells (AdMSC), in patients diagnosed as knee osteoarthritis. Following a 2-week screening period, approximately 140 subjects will be randomly assigned into one of the following two arms in a 1:1 ratio (1 JointStem : 1 Placebo). After each subject completes 48-Weeks visit (Visit 8) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.

Conditions

  • Osteoarthritis, Knee

Interventions

  • JointStemDrug

    Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)

  • Placebo ControlOther

    Normal Saline with autologous Serum

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Western Ontario and McMaster Universities Arthritis Index (WOMAC) function ScoreTime frame: Baseline and Week 48
  2. Visual Analog Scale (VAS) scoreTime frame: Baseline and Week 48

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • TriWest Research Associates

    El Cajon, California

  • BioSolutions Clinical Research Center

    La Mesa, California

  • Neurovations Research

    Napa, California

  • Newport Therapeutics

    Newport Beach, California

  • Source Healthcare

    Santa Monica, California

  • Keimyung University Dongsan Hospital

    Daegu, Korea, South Korea

  • Kyung Hee University Medical Center

    Seoul, Korea, South Korea

  • Kyung Hee University Hospital At Gangdong

    Seoul, Korea, South Korea

  • Smg-Snu Boramae Medical Center

    Seoul, Korea, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.